Hemp Gazette on MMJ and EXCLUSIVE IMPORT from Canada.
Australian Company Seeks To Import Medical Cannabis Tablets.
QBL subsidiary MCL has inked a deal with Canada’s Canntab Therapeutics to bring Canntab XR tablets into Australia.
The tablets are designed to deliver cannabinoids over a number of hours and have varying levels of THC and/or CBD. The company says the tablets take the guesswork out of cannabis medicines, which will make doctors more comfortable in prescribing them.
The enthusiastic announcement from QBL regarding the joint venture agreement claims Canntab is a “game-changing” medicine.
“Everyone knows someone who could benefit from this new technology,” said Pnina Feldman, QBL Executive Chairperson.
Canntab CEO Jeff Renwick says the deal enables the company to bring a significant advancement in cannabis-based medicines to Australia.
The QBL subsidiary MCL will now need to work towards securing the necessary approvals in order to import the product into Australia, which it is confident in obtaining. The company will also have first rights to distribute the products throughout Asia.
“We believe that the patents filed and pending protects key features of our IP, and positions Canntab to be the definitive Cannabis delivery method of choice among the established medical professions and ever- expanding number of Australians using cannabis every day for medical purposes, and an even greater number who would find benefits from its use,” states the announcement.
Each of Canntab’s five products is available in different dosage levels (2.5mg, 5mg, and 10mg) and in instant and stable extended release. The extended-release products are designed to release the active pharmaceutical ingredient at a predetermined rate in order to maintain a constant concentration over a specific period of time; which could be up to 18 hours.
Four of the products contain THC or THC and CBD, while Canntab “Yellow” tablets only contain CBD. It’s been a busy couple of weeks for Medical Cannabis Limited. Late last month we reported it had teamed up with Australia’s Algae.Tec Ltd (ASX:AEB) in a project researching cannabis-based veterinary medications.
ABOUT US
Hemp Gazette is a medicinal marijuana and industrial hemp information website. Based in Australia, we publish the latest breaking legal, medical and business news, research and industry reports from around the world.
Here you have the opportunity to take advantage on facts and info from QBL. Like the QBL on ASX website chapter, who can provide verified facts; here is regulated on-line stockbrokers suggestion, no games info and a good sum up. Voluntary suspension is requested regarding a significant and strategic acquisition by QBL’s subsidiary Medical Cannabis Limited until next FRIDAY or before, june 1. Contact information to the QBL Investor service, who can reply on questions. https://www.queenslandbauxite.com/
(different timezone be aware)
Australian Company Seeks To Import Medical Cannabis Tablets.
QBL subsidiary MCL has inked a deal with Canada’s Canntab Therapeutics to bring Canntab XR tablets into Australia.
The tablets are designed to deliver cannabinoids over a number of hours and have varying levels of THC and/or CBD. The company says the tablets take the guesswork out of cannabis medicines, which will make doctors more comfortable in prescribing them.
The enthusiastic announcement from QBL regarding the joint venture agreement claims Canntab is a “game-changing” medicine.
“Everyone knows someone who could benefit from this new technology,” said Pnina Feldman, QBL Executive Chairperson.
Canntab CEO Jeff Renwick says the deal enables the company to bring a significant advancement in cannabis-based medicines to Australia.
The QBL subsidiary MCL will now need to work towards securing the necessary approvals in order to import the product into Australia, which it is confident in obtaining. The company will also have first rights to distribute the products throughout Asia.
“We believe that the patents filed and pending protects key features of our IP, and positions Canntab to be the definitive Cannabis delivery method of choice among the established medical professions and ever- expanding number of Australians using cannabis every day for medical purposes, and an even greater number who would find benefits from its use,” states the announcement.
Each of Canntab’s five products is available in different dosage levels (2.5mg, 5mg, and 10mg) and in instant and stable extended release. The extended-release products are designed to release the active pharmaceutical ingredient at a predetermined rate in order to maintain a constant concentration over a specific period of time; which could be up to 18 hours.
Four of the products contain THC or THC and CBD, while Canntab “Yellow” tablets only contain CBD. It’s been a busy couple of weeks for Medical Cannabis Limited. Late last month we reported it had teamed up with Australia’s Algae.Tec Ltd (ASX:AEB) in a project researching cannabis-based veterinary medications.
ABOUT US
Hemp Gazette is a medicinal marijuana and industrial hemp information website. Based in Australia, we publish the latest breaking legal, medical and business news, research and industry reports from around the world.
Here you have the opportunity to take advantage on facts and info from QBL. Like the QBL on ASX website chapter, who can provide verified facts; here is regulated on-line stockbrokers suggestion, no games info and a good sum up. Voluntary suspension is requested regarding a significant and strategic acquisition by QBL’s subsidiary Medical Cannabis Limited until next FRIDAY or before, june 1. Contact information to the QBL Investor service, who can reply on questions. https://www.queenslandbauxite.com/
(different timezone be aware)
Robert
